Research Article

HPV-Related Prognostic Signature Predicts Survival in Head and Neck Squamous Cell Carcinoma

Hongyu Zhao,1 Fengxu Wang,2,3 Xuehai Wang,3 Xinyuan Zhao,3 and Jinfeng Ji2

1Department of Radiotherapy Oncology, Affiliated Hospital of Nantong University, Nantong 226000, China
2Department of Integrated Traditional Chinese and Western Internal Medicine, Affiliated Tumor Hospital of Nantong University, Nantong Tumor Hospital, Nantong 226631, China
3Department of Occupational Medicine and Environmental Toxicology, Nantong Key Laboratory of Environmental Toxicology, School of Public Health, Nantong University, Nantong 226019, China

Correspondence should be addressed to Xinyuan Zhao; zhaoxinyuan@ntu.edu.cn and Jinfeng Ji; jijfeng@163.com

Received 16 September 2022; Revised 3 October 2022; Accepted 6 October 2022; Published 15 November 2022

Academic Editor: Feng Jiang

Copyright © 2022 Hongyu Zhao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Head and neck squamous cell carcinoma (HNSCC) is one of the most common cancers, worldwide. Considering the role of human papillomavirus (HPV) in tumor development and sensitivity to treatment of HNSCC, we aimed to explore the prognostic classification ability of HPV-related signatures in head and neck cancer. Methods. HPV-related signatures were screened out based on Gene Expression Omnibus (GEO) and the Cancer Genome Atlas (TCGA) databases. HPV-related signatures with prognostic value were identified through univariate Cox regression analysis and a risk signature was established by least absolute shrinkage and selection operator (LASSO). Further, we developed a nomogram by integrating independent prognostic factors. Results. A total of 55 HPV-associated signatures were differentially expressed and ten of them were associated with prognosis of HNSCC patients. The prognostic signature based on CDKN2A, CELSR3, DMRTA2, SERPINE1, TJP3, FADD, and IGF2BP2 expression was constructed. Univariate and multivariate regression analyses demonstrated that the novel prognostic signature was an independent prognostic factor of HNSCC. The nomogram integrating the prognostic signature and other independent prognostic factors was developed. Conclusion. In summary, the prognostic signature of the HPV-related signatures might serve as an important prognostic biomarker for patients with HNSCC.

1. Introduction

Nearly 95% of head and neck cancer cases are caused by head and neck squamous cell carcinoma (HNSCC), considered the sixth most common form of cancer globally [1]. It has been reported that, despite advances in treatment modalities, outcomes of HNSCC patients have not been improved significantly [2]. Local invasion and distant metastasis at first diagnosis are the main reasons for their worse prognosis [1]. Therefore, it is urgent to construct new prognostic models to aid early clinical diagnosis.

As far as etiology is concerned, HNSCC is primarily caused by tobacco and alcohol use [3]. Throughout the world, research studies on HPV have proliferated in recent years [4]. Globally, approximately 25% of the number of head and neck cancer cases are caused by HPV infection [4]. Also, HPV causes almost all cases of cervical cancer and a subset of other anogenital cancers [5].

In this study, we tried to identify HPV-related signatures and construct a novel prognostic model and nomogram by using sequencing data and clinically relevant information of patients with HNSCC. We expect to improve the diagnosis and prognosis of patients with head and neck cancer from the perspective of HPV.

2. Materials and Methods

2.1. Data Collection. To identify HPV-related signatures, we selected and downloaded GSE65858 cohort from Gene Expression Omnibus (GEO, https://www.ncbi.nlm.nih.gov/
2.6. Cox Regression Analyses and Construction of a Nomogram. Univariate and multivariate Cox regression analyses were used to evaluate independent prognostic factors in HNSCC. A nomogram integrating the independent prognostic factors was established by "rms" package [16]. Calibration curves and area under the curve (AUC) were used to verify the validity of the nomogram [17, 18] we constructed.

3. Results

3.1. Expression and Pathway Enrichment of HPV-Related Signatures in HNSCC Patients. We derived 1136 HPV-associated signatures with significant differences from the GSE65858 cohort (Figure 1(a), Supplemental Table 1). A total of 55 HPV-associated signatures were differentially expressed in TCGA cohort according to screening criteria (Figures 1(b)-1(c)). In the light of GO and KEGG pathway analyses, HPV-associated signatures were significantly accumulated in focal adhesion, ECM-receptor interaction, AGE-RAGE signaling pathway in diabetic complications, protein digestion and absorption, and relaxin signaling pathway (Figures 1(d)–1(e)). Also, a protein interaction network was constructed with tightly linked HPV-associated signatures (Figure 1(f)).

3.2. Construction and Validation of a Prognostic Model Based on HPV-Related Signatures in HNSCC Patients. Ten prognosis-related signatures were identified by univariate Cox regression analysis (Figure 2(a)). To avoid overfitting, LASSO regression was performed and selected seven HPV-related signatures for constructing the prognostic signature (Figures 2(b)-2(c)). Risk score = (-0.0413836017 920187 × Exp CDKN2A) + (-0.365345241419471 × Exp CELSR3) + (-0.0633132503419892 × Exp DMRTA2) + (0.0162329920245241 × Exp SERPINE1) + (-0.04689421 53601447 × Exp TJP3) + (0.12874495442016 × Exp FADD) + (0.139702586686539 × Exp IGF2BP2).

Kaplan–Meier survival curves showed a worse overall survival and progression-free survival in the high-risk group when compared with the low-risk group (Figures 3(a)-3(b)). Meanwhile, the prognostic signature showed a great clustering ability compared with the cohort without genotyping (Figures 3(c)-3(d)). As shown in Figure 3(e), seven HPV-related signatures are ranked in different groups. The distribution of the risk scores and survival time are shown in Figures 3(f)-3(g). Meanwhile, the time-dependent ROC curves of the prognostic signature were performed and shown in Supplemental Figure 1A. The relationship between prognostic signature and clinicopathological factors is shown in Figures 4(a)-4(f). Interestingly, we found that the risk score was highly expressed in smokers compared to nonsmokers (p = 0.00046, Figure 4(e)). In addition, HPV-negative patients had a significantly higher risk value than HPV-positive patients with HNSCC (Supplemental Figure 1B).

3.3. Immune Infiltration Analysis. Through CIBERSORT algorithm, we found that naive B cells, plasma cells, CD8 T cells, activated memory CD4 T cells, follicular helper T cells, regulatory T cells (Tregs), gamma delta T cells, and
resting mast cells were highly enriched in the low-risk group (Figure 5(a)) while resting memory CD4 T cells, M0 macrophages, activated dendritic cells, and eosinophils were highly enriched in the high-risk group (Figure 5(a)). Based on the ssGSEA algorithm, moreover, check-point, cytolytic-activity, HLA, inflammation-promoting, T cell co-
inhibition, T cell co-stimulation, and type II IFN response were highly enriched in the low-risk group (Figure 5(b)). Moreover, WH-4-023, an inhibitor of LCK/SRC, was found to be useful in the high-risk group through pRRophetic algorithm (Figures 5(c)-5(d)).

3.4. The Prognostic Signature Was an Independent Prognostic Factor for HNSCC Patients. Using both univariate and multivariate Cox regression analyses, age, stage, and the prognostic signature were found to be reliable independent predictors of HNSCC (Figures 6(a)-6(b)). Subsequently, a nomogram integrating independent prognostic factors with significant differences was developed to predict the one-, three-, and five-year OS of HNSCC patients (Figure 6(c)). In calibration curves, the predictive curves originated from the nomogram showed a high agreement with the ideal curve (Figure 6(d)). AUC values of the nomogram were 0.665, 0.679, and 0.645 for one-, three-, and five-year OS,
respectively, demonstrating a better predictive accuracy of the nomogram compared with that of a single clinical factor (Figures 6(e)–6(g)).

4. Discussion

Head and neck squamous cell carcinoma is a collection of epithelial tumors originating mainly from the mucosa of the oral cavity, oropharynx, larynx, or hypopharynx [19]. Despite continuous advances in treatment modalities, the prognosis of patients with head and neck cancer has not improved significantly over the past decades [20]. The high recurrence rate of patients and the low response to intervention treatments such as chemoradiotherapy are the main reasons for the poor prognosis of patients [21, 22].

In recent years, the popularization and rapid development of next-generation sequencing (NGS) technology have enabled us to have a new understanding and insight into the molecular landscape of different tumors [23]. For head and neck cancer, these advances provided new insights into the different molecular mechanisms of HNSCC, the tumor microenvironment (TME) and heterogeneity of HNSCC, and the diversity of clinical responses among HNSCC subtypes [23–25].

In this study, we attempted to construct a new prognostic model from the perspective of HPV by microarray and high-throughput sequencing data. The flowchart of this study is shown in Figure 7. On the basis of the important impact of HPV on HNSCC, we identified HPV-associated signatures by comparing the transcriptome data of HPV-positive and HPV-negative HNSCC patients from the GEO dataset. To achieve a larger sample size to justify the scientific quality of this research, TCGA database was used for subsequent analyses. Ultimately, 55 HPV-associated signatures were differentially expressed and were significantly accumulated in focal adhesion, ECM-receptor interaction, AGE-RAGE signaling pathway in diabetic complications, protein digestion and absorption, and relaxin signaling pathway. Subsequently, seven HPV-related signatures (CDKN2A, CELSR3, DMRTA2, SERPINE1, TJP3, FADD, and IGF2BP2) that enabled the classification of high- and low-risk HNSCC patients were screened out.

Among these prognostic HPV-associated signatures, we noted one of the interesting. Cyclin-dependent kinase
inhibitor 2A, also known as p16, plays a critical role in cell-cycle regulation [26]. In addition, infection with HPV leads to overexpression of p16, and thus p16 is often used as a common marker of HPV positivity [26, 27]. Recently, multiple studies have surfaced that p16 expression in head and neck cancers was independent of HPV infection and should not serve as a reliable marker for HPV infection [28, 29]. Consistent with previous studies, p16 functioned as a tumor suppressor in HNSCC patients of this study and as a risk score reducer in the prognostic model with a negative coef value.

Interestingly, in the present study, we found that smoking HNSCC patients had a higher risk value. These results indicated that smoking would affect HPV status as well as the expression of HPV-related signatures and may give clues to the mechanism of head and neck cancers. Through prognostic analysis, we validated the prognostic model’s validity and accuracy. In addition, immune infiltration analysis showed a higher level of immune cell infiltration in the low-risk group than that of the high-risk group, which may explain the worse prognosis in the high-risk group. To our knowledge, this study is the first attempt...
|   | pvalue | Hazard ratio |
|---|--------|-------------|
| Age | <0.001 | 1.021(1.009–1.034) |
| Gender | 0.053 | 0.754(0.566–1.004) |
| Grade | 0.332 | 1.109(0.900–1.366) |
| Stage | <0.001 | 1.420(1.185–1.700) |
| HPV−status | 0.211 | 0.539(0.204–1.420) |
| Smoking | 0.676 | 1.075(0.767–1.505) |
| Drinking | 0.824 | 0.968(0.727–1.288) |
| Risk | <0.001 | 1.972(1.497–2.596) |

**Figure 6: Continued.**
to construct a prognostic signature for head and neck cancer based on HPV-related genes. For the convenience of clinical application, a novel nomogram based on independent prognostic factors of head and neck cancer was constructed. Meanwhile, in our study, we encountered a few limitations. The sample size and cohort size need to be expanded to guarantee their accuracy for this study. More patients with HNSCC and more prospective clinical trials need to be
5. Conclusion

We screened out differentially expressed signatures between HPV+ and HPV− HNSCC patients and developed a novel prognostic signature based on large sample datasets. Meanwhile, a novel nomogram was constructed by integrating independent prognostic factors.

Data Availability

The datasets analyzed during the current study are available in TCGA repository (https://portal.gdc.cancer.gov) and GEO (https://www.ncbi.nlm.nih.gov/geo/).

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Hongyu Zhao and Fengxu Wang performed the data curation and analysis. Xuehai Wang and Xinyuan Zhao analyzed and interpreted the results. Jinfeng Ji drafted and reviewed the manuscript. All authors read and approved the final manuscript. Hongyu Zhao and Fengxu Wang contributed equally to this work.

Acknowledgments

This study was supported by Natural Science Foundation of Jiangsu Province (BK20201444); Qing Lan Project for Excellent Young Key Teachers of Colleges and Universities of Jiangsu Province (2020).

Supplementary Materials

Supplemental Table 1: HPV-associated signatures with significant differences from the GSE65858 cohort. Supplemental Table 2: clinical information of the GEO cohort. Supplemental Table 3: clinical information of TCGA cohort. Supplemental Figure 1: ROC curves of the prognostic signature (A); the relationship between the prognostic signature and HPV status (B). (Supplementary Materials)

References

[1] A. Argiris, M. V. Karamouzis, D. Raben, and R. L. Ferris, "Head and neck cancer," The Lancet, vol. 371, no. 9625, pp. 1695–1709, 2008.
[2] S. H. Huang and B. O’Sullivan, "Overview of the 8th edition TNM classification for head and neck cancer," Current Treatment Options in Oncology, vol. 18, no. 7, p. 40, 2017.
[3] E. M. Rettig and G. D’Souza, "Epidemiology of head and neck cancer," Surgical Oncology Clinics of North America, vol. 24, no. 3, pp. 379–396, 2015.
[4] E. Tumban, “A current update on human papillomavirus-associated head and neck cancers,” Viruses, vol. 11, no. 10, p. E922, 2019.
[5] L. Zhai and E. Tumban, “Gardasil-9: a global survey of projected efficacy,” Antiviral Research, vol. 130, pp. 101–109, 2016.
[6] T. Barrett, S. E. Wilhite, P. Ledoux et al., “NCBI GEO: archive for functional genomics data sets--update,” Nucleic Acids Research, vol. 41, no. D1, pp. D991–D995, 2012.
[7] M. E. Ritchie, B. Phipson, D. Wu et al., “Limma powers differential expression analyses for RNA-sequencing and microarray studies,” Nucleic Acids Research, vol. 43, no. 7, p. e47, 2015.
[8] A. Blum, P. Wang, and J. C. Zenklusen, “SnapShot: TCGA-analyzed tumors,” Cell, vol. 173, no. 2, p. 530, 2018.
[9] The Gene Ontology Consortium, “Gene Ontology consortium: going forward,” Nucleic Acids Research, vol. 43, no. D1, pp. D1049–D1056, 2015.
[10] M. Kanehisa and S. Goto, “KEGG: kyoto encyclopedia of genes and genomes,” Nucleic Acids Research, vol. 28, no. 1, pp. 27–30, 2000.
[11] C. v Mering, M. Huynen, D. Jaeggi, S. Schmidt, P. Bork, and B. Snel, "STRING: a database of predicted functional associations between proteins," Nucleic Acids Research, vol. 31, no. 1, pp. 258–261, 2003.
[12] Y. Shen, H. Zhou, S. Dong, W. Dong, and L. Zhang, "Smoking patients with laryngeal cancer screened with a novel immunogenomics-based prognostic signature," Frontiers in Genetics, vol. 13, Article ID 961764, 2022.
[13] A. M. Newman, C. L. Liu, M. R. Green et al., “Robust enumeration of cell subsets from tissue expression profiles,” Nature Methods, vol. 12, no. 5, pp. 453–457, 2015.
[14] S. Shen, G. Wang, R. Zhang et al., “Development and validation of an immune gene-set based Prognostic signature in ovarian cancer,” EBioMedicine, vol. 40, pp. 318–326, 2019.
[15] W. Yang, J. Soares, P. Greninger et al., “Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells,” Nucleic Acids Research, vol. 41, no. D1, pp. D955–D961, 2012.
[16] Y. Shen, Q. Huang, Y. Zhang, C.-Y. Hsueh, and L. Zhou, “A novel signature derived from metabolism-related genes GPT and SMS to predict prognosis of laryngeal squamous cell carcinoma,” Cancer Cell International, vol. 22, no. 1, p. 226, 2022.
[17] A. C. Alba, T. Agoritsas, M. Walsh et al., “Discrimination and calibration of clinical prediction models: users’ guides to the medical literature,” JAMA, vol. 318, no. 14, pp. 1377–1384, 2017.
[18] D. L. Streiner and J. Cairney, “What’s under the ROC? An introduction to receiver operating characteristics curves,” Canadian Journal of Psychiatry, vol. 52, no. 2, pp. 121–128, 2007.
[19] D. Hashim, E. Genden, M. Posner, M. Hashibe, and P. Boffetta, "Head and neck cancer prevention: from primary prevention to impact of clinicians on reducing burden," Annals of Oncology, vol. 30, no. 5, pp. 744–756, 2019.
[20] X. Li, A. Lee, M. A. Cohen, E. J. Sherman, and N. Y. Lee, "Past, present and future of proton therapy for head and neck cancer," Oral Oncology, vol. 110, Article ID 104879, 2020.
[21] G. Tolstonog and C. Simon, "Trends in surgical research in head and neck cancer," Current Treatment Options in Oncology, vol. 18, no. 6, p. 38, 2017.
[22] W. M. Lydiatt, S. G. Patel, B. O’Sullivan et al., "Head and Neck cancers-major changes in the American Joint Committee on
cancer eighth edition cancer staging manual,” *CA: A Cancer Journal for Clinicians*, vol. 67, no. 2, pp. 122–137, 2017.

[23] P. S. Hammerman, D. N. Hayes, and J. R. Grandis, “Therapeutic insights from genomic studies of head and neck squamous cell carcinomas,” *Cancer Discovery*, vol. 5, no. 3, pp. 239–244, 2015.

[24] L. Tonella, M. Giannoccaro, S. Alfieri, S. Canevari, and L. De Cecco, “Gene expression signatures for head and neck cancer patient stratification: are results ready for clinical application?” *Current Treatment Options in Oncology*, vol. 18, no. 5, p. 32, 2017.

[25] C. R. Leemans, P. J. F. Snijders, and R. H. Brakenhoff, “The molecular landscape of head and neck cancer,” *Nature Reviews Cancer*, vol. 18, no. 5, pp. 269–282, 2018.

[26] C. Ndiaye, M. Mena, L. Alemany et al., “HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta-analysis,” *The Lancet Oncology*, vol. 15, no. 12, pp. 1319–1331, 2014.

[27] M. Lechner, A. R. Chakravarthy, V. Walter et al., “Frequent HPV-independent p16/INK4A overexpression in head and neck cancer,” *Oral Oncology*, vol. 83, pp. 32–37, 2018.

[28] C. Doll, C. Steffen, B. Beck-Broichsitter et al., “The prognostic significance of p16 and its role as a surrogate marker for human papilloma virus in oral squamous cell carcinoma: an analysis of 281 cases,” *Anticancer Research*, vol. 42, no. 5, pp. 2405–2413, 2022.

[29] V. Shyamsundar, S. V. Thangaraj, A. Krishnamurthy et al., “Exome sequencing with validations and expression of p16/cdkn2a shows no association with HPV in oral cancers,” *Asian Pacific Journal of Cancer Prevention*, vol. 23, no. 1, pp. 191–200, 2022.